Title

In Vitro Effects of Alternative Chemotherapeutics on a Virulent Strain of the Bovine Parasite Tritrichomonas foetus

Poster Number

28

Format

Poster Presentation

Abstract/Artist Statement

Tritrichomonas foetus is a protozoan responsible for bovine trichomoniasis. Trichomoniasis in cattle is a disease characterized by self-limitation, and infects both male and female cows, with bulls being asymptomatic chronic carriers of the disease. Similar to trichomoniasis in humans, the protozoan can be treated in vitro using nitroimidazole drugs and its derivatives. However, nitroimidazole drugs are no longer approved by the FDA for treatment of bovine trichomoniasis. Currently, trichomoniasis has a prevalence of disease as high as 16% in natural-breeding range herds and the lack of pharmacological treatment for the disease as well as the impracticality of current control methods contribute to the necessity for new, more effective chemotherapeutics. In order to support the effort we have started to screen, in vitro, a compound library of 3,4- dichloroaniline amides, of which only a couple of shown promise for inhibition of parasite growth. Further trials of these compounds will confirm which compounds show promising ability at inhibiting parasite growth, at which point IC50 values will be determined for these compounds, as well as structure-activity relationships.

Location

DeRosa University Center, Ballroom B

Start Date

2-5-2009 1:00 PM

End Date

2-5-2009 3:00 PM

This document is currently not available here.

Share

COinS
 
May 2nd, 1:00 PM May 2nd, 3:00 PM

In Vitro Effects of Alternative Chemotherapeutics on a Virulent Strain of the Bovine Parasite Tritrichomonas foetus

DeRosa University Center, Ballroom B

Tritrichomonas foetus is a protozoan responsible for bovine trichomoniasis. Trichomoniasis in cattle is a disease characterized by self-limitation, and infects both male and female cows, with bulls being asymptomatic chronic carriers of the disease. Similar to trichomoniasis in humans, the protozoan can be treated in vitro using nitroimidazole drugs and its derivatives. However, nitroimidazole drugs are no longer approved by the FDA for treatment of bovine trichomoniasis. Currently, trichomoniasis has a prevalence of disease as high as 16% in natural-breeding range herds and the lack of pharmacological treatment for the disease as well as the impracticality of current control methods contribute to the necessity for new, more effective chemotherapeutics. In order to support the effort we have started to screen, in vitro, a compound library of 3,4- dichloroaniline amides, of which only a couple of shown promise for inhibition of parasite growth. Further trials of these compounds will confirm which compounds show promising ability at inhibiting parasite growth, at which point IC50 values will be determined for these compounds, as well as structure-activity relationships.